Cover Image

Multiple myeloma treatment strategies with novel agents in 2011: a european perspective

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with...

Full description

Saved in:
Bibliographic Details
Main Authors: Ludwig, Heinz (Author) , Beksac, Meral (Author) , Bladé, Joan (Author) , Cavenagh, Jamie (Author) , Cavo, Michele (Author) , Delforge, Michel (Author) , Dimopoulos, Meletios (Author) , Drach, Johannes (Author) , Einsele, Hermann (Author) , Facon, Thierry (Author) , Goldschmidt, Hartmut (Author) , Harousseau, Jean‐Luc (Author) , Hess, Urs (Author) , Kropff, Martin (Author) , Leal da Costa, Fernando (Author) , Louw, Vernon (Author) , Magen‐Nativ, Hila (Author) , Mendeleeva, Larisa (Author) , Nahi, Hareth (Author) , Plesner, Torben (Author) , San‐Miguel, Jesús (Author) , Sonneveld, Pieter (Author) , Udvardy, Miklos (Author) , Sondergeld, Pia (Author) , Palumbo, Antonio (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: The oncologist
Year: 2011, Volume: 16, Issue: 4, Pages: 388-403
ISSN:1549-490X
DOI:10.1634/theoncologist.2010-0386
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1634/theoncologist.2010-0386
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/oncolo/article/16/4/388/6400791?login=true
Get full text
Author Notes:Heinz Ludwig, Meral Beksac, Joan Bladé, Jamie Cavenagh, Michele Cavo, Michel Delforge, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Jean‐Luc Harousseau, Urs Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen‐Nativ, Larisa Mendeleeva, Hareth Nahi, Torben Plesner, Jesús San‐Miguel, Pieter Sonneveld, Miklos Udvardy, Pia Sondergeld, Antonio Palumbo
Description
Summary:The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence‐based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.
Item Description:Gesehen am 11.11.2022
Physical Description:Online Resource
ISSN:1549-490X
DOI:10.1634/theoncologist.2010-0386

Similar Items